The progress in the current research has encouraged scientists to use therapeutic antibodies to treat a number of health illnesses such as cancer, certain autoimmune diseases, and others. At present, the modernized antibody treatments and the conventionally used methods involve the use of injections to directly inject into the bloodstreams which are not only invasive but also possess systemic side effects. In the upcoming days, the researchers are planning on developing edible antibodies to avoid painful invasive methods and other associated side effects. To date, the oral form of entry of the antibodies in the body has never been observed or practiced before as it is believed to be damaged during the process of digestion.
The presently designed antibody can withstand the digestion process and enable the treatment to survive. The newly engineered antibody is trained to treat gut-related problems through a local mode of administration rather than the traditional injection mode. The scientists have made of yeast cells or soybean seeds and already existing food processing technology for the manufacturing process of the edible antibodies. The straight forward manufacturing process is followed in case of the antibody production just like the one used in certain other food item manufacturing.
The new product is in the powdered form containing the antibodies belonging to either the humans or animals, which is consumable. As per the researchers, the powder does not have to be enclosed in a capsule rather it can be directly consumed along with the food. The new product has already cleared the preclinical trial as it has proved successful in piglets having diarrhea caused by Escherichia coli. The antibodies seem more fruitful and safe compared to the antibiotics. It is expected to be the future treatment method for many human gut conditions, infections, and also helping lowering gut diseases in the susceptible population. MD Shoba Navai from the Center for Cell and Gene Therapy along with her team has developed a combination of chimeric antigen receptor (CAR) T cells and chemotherapy to attack the protein HER2. It is a safe and clinically responsive in adults and children with advanced HER2-positive sarcoma.